Statistics from Altmetric.com
Preterm infants are at increased risk of morbidity and mortality from rotavirus gastroenteritis.1 The impact of vaccines in reducing rotavirus-associated gastroenteritis admissions has been documented internationally, including in Australia.2 The UK introduced a live attenuated oral rotavirus vaccine (Rotarix (GSK)) for infants in July 2013. Healthcare providers need to be aware that the vaccine has strict administration age cut-offs, with the first dose to be administered by 14 weeks and the second dose by 24 weeks of age.3 These strict timelines are due to a small but significant increase in intussusception following oral rotavirus vaccines.4
Immunisations are often delayed in preterm infants despite recommendations that they …
Contributors NWC designed the study and wrote the first draft of the letter. RWH provide the audit case details and revised the manuscript.
Competing interests NWC has acted as chief investigators for epidemiological studies sponsored by vaccine manufacturers (CSL) and serological testing (Merck). All payments, including for sitting on advisory boards (Pfizer), are paid directly to an administrative fund held by Murdoch Childrens Research Institute. RWH has no conflicts of interest to declare.
Ethics approval RCH Ethics committee.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.